美股异动 | 推出下一代癌症免疫治疗平台 HCW Biologics(HCWB.US)暴涨近70%

Group 1 - HCW Biologics experienced a nearly 70% surge in stock price, reaching $5.81, following the announcement of a second-generation immunotherapy drug based on Pembrolizumab targeting solid tumors, particularly pancreatic and ovarian cancers [1] - The company utilizes a novel proprietary TRBC product discovery and development platform technology for its new drug [1] - Since the introduction of immune checkpoint inhibitors (ICIs) in cancer treatment in 2011, they have been recognized as breakthrough therapies, although the company noted that preclinical and clinical studies indicate ICIs lack co-stimulatory activity of immune cells, reducing their anti-tumor efficacy [1]